Acute Respiratory Distress Syndrome is a state in which the organs fail and the lungs, specifically the alveoli, are flooded with fluids that reduce the delivery of oxygen to the vital organs. It is commonly attributed to diseases and conditions like sepsis, pneumonia, or toxic inhalation injuries. The symptoms of the disease are difficulties in breathing, hypotension, and increased rate of respiration. Mechanical ventilation, the use of intravenous fluids and administration of inhaled medications are commonly used in managing ARDS. The occurrence is coupled with more than 3 million participants globally resulting from air pollution and the breath-taking of toxic gases. According to WHO estimates, 3 Million individuals develop ARDS annually all over the world.
Promptly recognizing acute respiratory distress syndrome is crucial for initiating effective lung-protective ventilation strategies. However, diagnosis is often delayed, with reported under-diagnosis rates as high as 40%. The likelihood of diagnosis increases with disease severity. The current clinical criteria have low specificity, and no biomarkers are available for diagnosis, but active research is ongoing. The indirect injuries such as severe bacterial infection, sepsis, severe bleeding, low blood pressure requiring blood transfusions, and pancreas inflammation. In addition, it is mentioned that the global market for Acute Respiratory Distress Syndrome was$1.00 billion in 2022.
Acute respiratory distress syndrome may result from exposure to environmental pollutants like air pollution and toxins, as well as from chronic conditions such as heart disease, diabetes, and obesity. Poorly managed chronic conditions increase the risk of developing acute respiratory distress syndrome. Beaufort is an FDA-approved medication for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants up to two years of age who are at risk of severe RSV disease.
The impact of Acute Respiratory Distress Syndrome on healthcare systems worldwide. It highlights increased admissions to critical care units and hospitals, with statistics from countries such as Australia, France, and the U.S. The importance of increasing investment in healthcare for Acute Respiratory Distress Syndrome to improve patient outcomes and reduce the burden of potentially fatal conditions is emphasized, along with the need for intensive medical intervention and advanced medical technologies. The global healthcare infrastructure investment is expected to experience significant growth by 2025, particularly in the Middle East, Africa, and Asia.
United States Acute Respiratory Distress Syndrome Market
The USA acute respiratory distress syndrome market is growing due to the increasing prevalence of acute lung injury, driven by factors such as the patient pool with ARDS. Companies across the United States have shifted their focus toward this therapeutic area to meet the unmet need for the acute respiratory distress syndrome treatment regimen. Emerging therapies are focused on treating acute respiratory distress syndrome and are expected to impact market size significantly. According to the WHO, 200,000 people in the United States are affected by ARDS every year. Chronic lung diseases like asthma are a significant cause of ARDS, with over 34 million people in the U.S. living with chronic lung diseases like asthma and COPD.Global Acute Respiratory Distress Syndrome Company Analysis
Prominent players in the Acute Respiratory Distress Syndrome Market are Silence Therapeutics plc, Gilead Sciences Inc., Terumo Corporation, Getinge AB, Livanova Plc, Medtronic, Inc., Fresenius Se & Co. KGAA, Nipro, and Pfizer Inc.Acute Respiratory Distress Syndrome Company New
Jan 2024: LivaNova PLC is winding down its ACS Business Unit to focus on its core Cardiopulmonary and Neuromodulation Business Units. The wind-down process is expected to be completed by the end of 2024.Feb 2024: Silence Therapeutics received a $10 million milestone payment from AstraZeneca to begin a phase 1 clinical trial for their siRNA collaboration.
March 2024: Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced exclusive license agreements for Xilio's tumor-activated IL-12 program, XTX301.
March 2024: Terumo Blood and Cell Technologies partnered with the CiRA Foundation to develop automated iPS cell manufacturing.
March 2024: Getinge has announced the U.S. launch of the Corin Operating Table and Ezea Surgical Light at AORN.
March 2024: The FDA has approved Medtronic's Evolut FX+ TAVR system for treating severe aortic stenosis. This system retains the benefits of the earlier Evolut TAVR platform and allows easier coronary access.
April 2024, Pfizer Inc. has reported successful results from Phase 3 clinical trials for ABRYSVO, a single-dose vaccine designed for adults aged 18 to 59 at risk of severe RSV-associated LRTD.
In December 2022, Terumo Corp. and Kyowa Kirin Co. launched "G-Lasta Subcutaneous Injection 3.6 mg BodyPod" in Japan.
Type - Market is divided into 2 viewpoints
1. Diagnosis2. Treatment
End User - Market is divided into 4 viewpoints
1. Hospitals2. Specialty clinics
3. Home healthcare
4. Others
Countries - Market is divided into 25 Country Acute Respiratory Distress Syndrome Industry
1. North America1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa
Key Players: All key players have been covered from 4 points
- Overviews
- Recent Developments
- Product Portfolio
- Revenue
Company Analysis:
1. Silence Therapeutics plc2. Gilead Seiences Inc.
3. Terumo Corporation
4. Getinge AB
5. Livanova Plc
6. Medtronic, Inc.
7. Fresenius Se & Co. KGAA
8. Nipro
9. Pfizer Inc.
Table of Contents
Companies Mentioned
- Silence Therapeutics plc
- Gilead Seiences Inc.
- Terumo Corporation
- Getinge AB
- Livanova Plc
- Medtronic, Inc.
- Fresenius Se & Co. KGAA
- Nipro
- Pfizer Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | June 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.23 Billion |
| Forecasted Market Value ( USD | $ 2.36 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
